Update on bevacizumab and other angiogenesis inhibitors for brain cancer

Author： Rinne Mikael L Lee Eudocia Q Nayak Lakshmi Norden Andrew D Beroukhim Rameen Wen Patrick Y Reardon David A

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.18, Iss.2, 2013-06, pp. : 137-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

By Tomao Federica Papa Anselmo Rossi Luigi Caruso Davide Zoratto Federica Benedetti Panici Pierluigi Tomao Silverio

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 37-53

Informa Healthcare

Access to resources Recommend Favorite

Angiogenesis inhibitors in the treatment of cancer

By Rhee Jay Hoff Paulo M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 10, 2005-08 ,pp. : 1701-1711

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled

Current Molecular Pharmacology, Vol. 5, Iss. 3, 2012-11 ,pp. : 382-391

Bentham Science Publishers

Access to resources Recommend Favorite

Angiogenesis inhibitors in the treatment of prostate cancer

By Kluetz Paul G Figg William D Dahut William L

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 233-247

Informa Healthcare

Access to resources Recommend Favorite

PARP inhibitors in cancer therapy: an update

By Papeo Gianluca Casale Elena Montagnoli Alessia Cirla Alessandra

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 503-514

Informa Healthcare

Access to resources Recommend Favorite